Szturz P - Search Results

1

Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.

Cristina V, Herrera-Gómez RG, Szturz P, Espeli V, Siano M. Cristina V, et al. Among authors: szturz p. Int J Mol Sci. 2019 Oct 30;20(21):5399. doi: 10.3390/ijms20215399. Int J Mol Sci. 2019. PMID: 31671550 Free PMC article. Review.

2

Understanding c-MET signalling in squamous cell carcinoma of the head & neck.

Szturz P, Raymond E, Abitbol C, Albert S, de Gramont A, Faivre S. Szturz P, et al. Crit Rev Oncol Hematol. 2017 Mar;111:39-51. doi: 10.1016/j.critrevonc.2017.01.004. Epub 2017 Jan 12. Crit Rev Oncol Hematol. 2017. PMID: 28259294 Review.

3

Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice.

Szturz P, Bossi P, Vermorken JB. Szturz P, et al. Curr Opin Otolaryngol Head Neck Surg. 2019 Apr;27(2):142-150. doi: 10.1097/MOO.0000000000000526. Curr Opin Otolaryngol Head Neck Surg. 2019. PMID: 30694914 Review.

4

Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice.

Szturz P, Cristina V, Herrera Gómez RG, Bourhis J, Simon C, Vermorken JB. Szturz P, et al. Front Oncol. 2019 Jun 11;9:464. doi: 10.3389/fonc.2019.00464. eCollection 2019. Front Oncol. 2019. PMID: 31245288 Free PMC article. Review.

5

[Anaplastic thyroid carcinoma : new therapeutic approaches].

Stamatiou A, Herrera-Gómez RG, Szturz P, Bisig B, Romano E, Sykiotis G, Gorostidi F, La Rosa S, Kopp P, Cristina V. Stamatiou A, et al. Among authors: szturz p. Rev Med Suisse. 2021 May 19;17(739):962-966. Rev Med Suisse. 2021. PMID: 34009754 French.

6

Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.

Szturz P, Specenier P, Van Laer C, Van Den Weyngaert D, Corthouts B, Carp L, Van Marck E, Vanderveken O, Vermorken JB. Szturz P, et al. Eur Arch Otorhinolaryngol. 2016 Jun;273(6):1629-36. doi: 10.1007/s00405-015-3673-y. Epub 2015 Jun 5. Eur Arch Otorhinolaryngol. 2016. PMID: 26044403

7

Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al.

Szturz P, Faivre S. Szturz P, et al. Oral Oncol. 2016 Nov;62:e3-e4. doi: 10.1016/j.oraloncology.2016.08.007. Epub 2016 Aug 28. Oral Oncol. 2016. PMID: 27578499 No abstract available.

8

How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

Szturz P, Seiwert TY, Vermorken JB. Szturz P, et al. J Clin Oncol. 2017 Jul 10;35(20):2229-2231. doi: 10.1200/JCO.2016.71.8072. Epub 2017 May 4. J Clin Oncol. 2017. PMID: 28471725 No abstract available.

9

Immunotherapy in head and neck cancer: aiming at EXTREME precision.

Szturz P, Vermorken JB. Szturz P, et al. BMC Med. 2017 Jun 2;15(1):110. doi: 10.1186/s12916-017-0879-4. BMC Med. 2017. PMID: 28571578 Free PMC article.

10

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.

Szturz P, Budíková M, Vermorken JB, Horová I, Gál B, Raymond E, de Gramont A, Faivre S. Szturz P, et al. Oral Oncol. 2017 Nov;74:68-76. doi: 10.1016/j.oraloncology.2017.09.009. Epub 2017 Sep 27. Oral Oncol. 2017. PMID: 29103754 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters